Abstract
In a large, prospective, observational study of pregnancy and child development, the antinauseant drugs prescribed to gravides for nausea and vomiting in the first 84 days of pregnancy were evaluated for their teratogenic potential. The severe congenital anomaly rates per 100 liveborn children and ther perinatal death rates of this group did not differ from the rates of the group with untreated nausea and vomiting. There was no indication that the phenothiazine derivatives, specifically the prochlorperazine derivative, as well as meclizine, cylizine, and Bendectin were associated with teratogenicity. The trimethobenzamide drug gave a slight suggestion of an excess of severe congenital anomalies.
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Abnormalities, Drug-Induced / epidemiology
-
Abnormalities, Drug-Induced / mortality
-
Antiemetics / adverse effects*
-
Antiemetics / therapeutic use
-
Clinical Trials as Topic
-
Cyclizine / adverse effects
-
Dicyclomine / adverse effects
-
Doxylamine / adverse effects
-
Drug Combinations
-
Drug Evaluation
-
Female
-
Fetal Death / epidemiology
-
Humans
-
Hyperemesis Gravidarum / drug therapy*
-
Meclizine / adverse effects
-
Patient Compliance
-
Phenothiazines / adverse effects
-
Pregnancy
-
Prochlorperazine / adverse effects
-
Prospective Studies
-
Pyridoxine / adverse effects
-
Teratogens*
Substances
-
Antiemetics
-
Drug Combinations
-
Phenothiazines
-
Teratogens
-
Meclizine
-
Dicyclomine
-
Doxylamine
-
Pyridoxine
-
Cyclizine
-
Prochlorperazine